Publications

• Comprehensive molecular profiling of patients with pancreatic adenocarcinoma: A single institution’s experience.

  (Kamgar M, Dyson G, Diab M, Tesfaye AA, Korn WM, Shields AF, Philip AP.) Journal of Clinical Oncology . 36, no. 15_suppl.e16236 06/01/2018

• Comparison of fluoropyrimidine based (FP)and taxane based platinum doublets (TP) in frontline treatment of patients with metastatic gastroesophageal adenocarcinomas (mGEAC): A retrospective analysis

  (2.tIsmail H, Mohamed A, Song Y, Abdallah N, Surapaneni M, Kim S, Kamgar M, Mettu J, Akhras A, Ahmed A, Philip PA, Shields AF, Tesfaye A.) American Society of Clinical Oncology. 35, no. 15_suppl.e15604 05/30/2017

• Comparative analysis of the effect of bevacizumab maintenance regimens after first-line chemotherapy in patients with metastatic colorectal cancer (MCRC): A single institution experience

  (Song Y, Mohamed A, Ismail H, Abdallah N, Suprapaneni M, Dyson G, Kamgar M, Akhras A, Mettu J, Ahmed A, Tesfaye AA, Philip PA, Shields AF.) Journal of Clinical Oncology. 35, no. 15_suppl.e15032 05/30/2017

• Preclinical Assessment with Clinical Validation of Selinexor with Gemcitabine and Nab-Paclitaxel for the Treatment of Pancreatic Ductal Adenocarcinoma.

  (Azmi AS, Khan HY, Muqbil I, Aboukameel A, Neggers JE, Daelemans D, Mahipal A, Dyson G, Kamgar M, Al-Hallak MN, Tesfaye A, Kim S, Shidham V, M Mohammad R, Philip PA.) Clin Cancer Res. 2020 Mar 15;26(6):1338-1348 PMID: 31831564 PMCID: PMC7073299 12/14/2019

• PAK4-NAMPT Dual Inhibition as a Novel Strategy for Therapy Resistant Pancreatic Neuroendocrine Tumors.

  (Mpilla G, Aboukameel A, Muqbil I, Kim S, Beydoun R, Philip PA, Mohammad RM, Kamgar M, Shidham V, Senapedis W, Baloglu E, Li J, Dyson G, Xue Y, El-Rayes B, Azmi AS.) Cancers (Basel). 2019 Nov 29;11(12) PMID: 31795447 PMCID: PMC6966587 12/05/2019

• Goals of Treatment Sequencing for Localized Pancreatic Cancer.

  (Evans DB, Kamgar M, Tsai S.) Ann Surg Oncol. 2019 Nov;26(12):3815-3819 PMID: 31493126 SCOPUS ID: 2-s2.0-85073126378 09/08/2019

• How I Treat Resectable Pancreatic Cancer With Adjuvant Therapy

  (PA Philip, M Kamgar.) Handbook of Gastrointestinal Cancers: Evidence-Based Treatment and Multidisciplinary Patient Care. PA Philip, M Kamgar (2019).'How I Treat Resectable Pancreatic Cancer With Adjuvant Therapy', in T Bekaii-Saab, B El-Rayes, T Pawlik (ed.) Handbook of Gastrointestinal Cancers: Evidence-Based Treatment and Multidisciplinary Patient Care: Springer Publishing Company, PP. 183-190 08/13/2019

• The evolution into personalized therapies in pancreatic ductal adenocarcinoma: challenges and opportunities.

  (Tesfaye AA, Kamgar M, Azmi A, Philip PA.) Expert Rev Anticancer Ther. 2018 02;18(2):131-148 PMID: 29254387 PMCID: PMC6121777 12/20/2017

• Can aminotransferase-to-platelet ratio index and other non-invasive markers effectively reduce liver biopsies for renal transplant evaluation of hepatitis C virus-positive patients?

  (Jiang Y, Huang E, Mehrnia A, Kamgar M, Pham PT, Ogunorunyinka O, Brown I, Danovitch GM, Bunnapradist S.) Nephrol Dial Transplant. 2014 Jun;29(6):1247-52 PMID: 24353319 12/20/2013

• Renal Transplant Outcomes in Waitlist Candidates with a Previous Inactive Status Due to Being Temporarily Too Sick.

  (Leeaphorn N, Sampaio MS, Natal N, Mehrnia A, Kamgar M, Huang E, Kalantar-Zadeh K, Kaplan B, Bunnapradist S.) Clin Transpl. 2014:117-24 PMID: 26281135 01/01/2014

• Chapter 5 - Protocols in genetic mice models of pancreatic cancer

  (Al-Qambar B, Chaker M, Kamgar M, Tesfaye A, Uwe-Wagner K, Azmi SA.) . In Azmi AS & Mohammad RM (Eds.), Animal Models in Cancer Drug Discovery: Academic Press, 107-123 01/01/2019

• Protocols in genetic mice models of pancreatic cancer

  (Al-Qambar B, Chaker M, Kamgar M, Tesfaye A, Uwe-Wagner K, Azmi AS.) . In Azmi AS & Mohammad RM (Eds.), Animal Models in Cancer Drug Discovery: Academic Press107-123 01/01/2019